© Peter Scott
US pharma bosses are considering moving their production home, which could have far-reaching consequences for global pharma supply chains. The obstacles are challenging, though.
Last week pharma giant Eli Lilly announced plans to spend at least $27bn on the construction of four new manufacturing facilities in the US. Three, set to come onstream over the coming five years, will be turning out raw ingredients for…
Boutique Travel VC raises investment cap from $1.5M to $10M to lead rounds and support portfolio companies through growth Travel...
Read moreDetails
